Clinical trial registration, sponsored by University of Minnesota, registered 22 Sep 2026.
Phase 1 · not yet recruiting · n = 18
Tags: Registry, Psilocybin, Depression.
New registrations include psilocybin for methamphetamine use disorder, borderline personality disorder, nicotine craving and premenstrual dysphoric disorder, and a National Institute on Aging trial pairing psilocybin with cognitive training. Results were posted for psilocybin in depression and anxiety in Parkinson's disease.
How much weight it carries: Registrations show what is being attempted, not what was found. (Registry, Plans, not results)
newly registered open-label proof-of-concept adding two 25 mg psilocybin sessions to an ongoing DBT program for borderline personality disorder, at Minnesota
How much weight it carries: Trial registry movements: what is being attempted, not what was found. (Registry, Plans, not results)